Gene Therapy Company Co-founded by Department Faculty Dr. James Wilson Raises Almost $139 Million in IPO
September 18, 2015
Regenxbio Inc., a gene-therapy firm that creates adeno-associated viruses, which are designed to get inside genes and change mutations that cause disease, started trading on NASDAQ on September 17. Regenxbio was cofounded by Dr. James Wilson, director of the Gene Therapy Program and the Orphan Disease Center at Penn. The company went public through a $138.6 million initial public offering (IPO).
Philadelphia Business Journal coverage.
Genetic Engineering & Biotechnology News (GEN) coverage.